These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15645203)

  • 1. [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].
    Wobrock T; Scherk H; Falkai P
    Radiologe; 2005 Feb; 45(2):124-30, 132-6. PubMed ID: 15645203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnetic resonance spectroscopy in schizophrenia].
    Delamillieure P; Constans JM; Fernandez J; Dollfus S
    Encephale; 2000; 26(1):21-31. PubMed ID: 10875059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study.
    Weber-Fahr W; Englisch S; Esser A; Tunc-Skarka N; Meyer-Lindenberg A; Ende G; Zink M
    Psychiatry Res; 2013 Dec; 214(3):365-73. PubMed ID: 24045051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia.
    Reddy R; Keshavan MS
    Prostaglandins Leukot Essent Fatty Acids; 2003 Dec; 69(6):401-5. PubMed ID: 14623493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy.
    Fukuzako H
    World J Biol Psychiatry; 2001 Apr; 2(2):70-82. PubMed ID: 12587188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla.
    Théberge J; Al-Semaan Y; Jensen JE; Williamson PC; Neufeld RW; Menon RS; Schaefer B; Densmore M; Drost DJ
    Psychiatry Res; 2004 Nov; 132(1):33-9. PubMed ID: 15546701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phosphorus 31 magnetic resonance spectroscopy in schizophrenia research. Pathophysiology of cerebral metabolism of high-energy phosphate and membrane phospholipids].
    Riehemann S; Volz HP; Smesny S; Hübner G; Wenda B; Rössger G; Sauer H
    Nervenarzt; 2000 May; 71(5):354-63. PubMed ID: 10846710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative proton-decoupled 31P MRS of the schizophrenic brain in vivo.
    Blüml S; Tan J; Harris K; Adatia N; Karme A; Sproull T; Ross B
    J Comput Assist Tomogr; 1999; 23(2):272-5. PubMed ID: 10096336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia.
    Rowland L; Bustillo JR; Lauriello J
    Semin Clin Neuropsychiatry; 2001 Apr; 6(2):121-30. PubMed ID: 11296312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla.
    Jensen JE; Miller J; Williamson PC; Neufeld RW; Menon RS; Malla A; Manchanda R; Schaefer B; Densmore M; Drost DJ
    Psychiatry Res; 2006 Mar; 146(2):127-35. PubMed ID: 16497488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 31P NMR spectroscopy of phospholipid metabolites in postmortem schizophrenic brain.
    Komoroski RA; Pearce JM; Mrak RE
    Magn Reson Med; 2008 Mar; 59(3):469-74. PubMed ID: 18306399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.
    Abbott C; Bustillo J
    Curr Opin Psychiatry; 2006 Mar; 19(2):135-9. PubMed ID: 16612192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia: a 31P magnetic resonance spectroscopy study.
    Jayakumar PN; Gangadhar BN; Subbakrishna DK; Janakiramaiah N; Srinivas JS; Keshavan MS
    Biol Psychiatry; 2003 Aug; 54(4):491-4. PubMed ID: 12915294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton magnetic resonance spectroscopy changes after antipsychotic treatment.
    Szulc A; Galinska-Skok B; Waszkiewicz N; Bibulowicz D; Konarzewska B; Tarasow E
    Curr Med Chem; 2013; 20(3):414-27. PubMed ID: 23157634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia.
    Smesny S; Rosburg T; Nenadic I; Fenk KP; Kunstmann S; Rzanny R; Volz HP; Sauer H
    Neuroimage; 2007 Apr; 35(2):729-37. PubMed ID: 17276699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism.
    Yacubian J; de Castro CC; Ometto M; Barbosa E; de Camargo CP; Tavares H; Cerri GG; Gattaz WF
    Schizophr Res; 2002 Dec; 58(2-3):117-22. PubMed ID: 12409151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain cell membrane motion-restricted phospholipids: a cerebral 31-phosphorus magnetic resonance spectroscopy study of patients with schizophrenia.
    Puri BK; Counsell SJ; Hamilton G
    Prostaglandins Leukot Essent Fatty Acids; 2008 Dec; 79(6):233-5. PubMed ID: 18842398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging.
    Bertolino A; Nawroz S; Mattay VS; Barnett AS; Duyn JH; Moonen CT; Frank JA; Tedeschi G; Weinberger DR
    Am J Psychiatry; 1996 Dec; 153(12):1554-63. PubMed ID: 8942451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies.
    Haszto CS; Stanley JA; Iyengar S; Prasad KM
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Mar; 5(3):264-280. PubMed ID: 31748123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.
    Tanaka Y; Obata T; Sassa T; Yoshitome E; Asai Y; Ikehira H; Suhara T; Okubo Y; Nishikawa T
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):365-72. PubMed ID: 16732755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.